Insider Trading (Form 4)
NASDAQ
Genenta Science CEO Pierluigi Paracchi acquired 100,000 stock options with an exercise price of $0.63, vesting over three years.
NASDAQ
Genenta Science's CMO and Head of Development, Francesco Galimi, acquired 20,000 stock options with an exercise price of $0.63, vesting over one year starting March 30, 2026.
NASDAQ
Genenta Science S.p.A.'s Chief Financial Officer, Richard B. Slansky, was granted 80,000 stock options with an exercise price of $0.63, vesting monthly over three years starting March 30, 2026.
Schedule 13D - Activist Investments
NASDAQ
A group of Genenta Science shareholders has filed a Schedule 13D, announcing their formation and intent to monitor corporate actions and challenge recent amendments to the company's articles of association.
Schedule 13G - Passive Investments
NASDAQ
SCHEDULE 13G/A: Genenta Science Insider Boosts Stake to 9.8%
Pierluigi Paracchi, a key individual, has increased his beneficial ownership in Genenta Science S.p.A. to 9.8% of ordinary shares.
NASDAQ
SCHEDULE 13G/A: Insider Pierluigi Paracchi Maintains Significant 12.6% Stake in Genenta Science S.p.A.
Pierluigi Paracchi, a key individual, has disclosed a beneficial ownership of 12.6% in Genenta Science S.p.A. as of December 31, 2024, according to a recent Schedule 13G Amendment No. 3 filing.